[go: up one dir, main page]

WO1995003011A1 - Gabarits de regeneration osseuse - Google Patents

Gabarits de regeneration osseuse Download PDF

Info

Publication number
WO1995003011A1
WO1995003011A1 PCT/US1994/008265 US9408265W WO9503011A1 WO 1995003011 A1 WO1995003011 A1 WO 1995003011A1 US 9408265 W US9408265 W US 9408265W WO 9503011 A1 WO9503011 A1 WO 9503011A1
Authority
WO
WIPO (PCT)
Prior art keywords
matrix
template
pore
polymer
biodegradable
Prior art date
Application number
PCT/US1994/008265
Other languages
English (en)
Other versions
WO1995003011A9 (fr
Inventor
Antonios G. Mikos
Original Assignee
Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rice University filed Critical Rice University
Priority to AU74028/94A priority Critical patent/AU7402894A/en
Publication of WO1995003011A1 publication Critical patent/WO1995003011A1/fr
Publication of WO1995003011A9 publication Critical patent/WO1995003011A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/3094—Designing or manufacturing processes
    • A61F2/30965—Reinforcing the prosthesis by embedding particles or fibres during moulding or dipping
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30108—Shapes
    • A61F2002/30199—Three-dimensional shapes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063—Three-dimensional shapes

Definitions

  • This invention relates to prosthetic templates providing mechanical strength and support for growth of normal tissues in the treatment of injured bone. More particularly, this invention provides a biodegradable, three dimensional template for replacement or repair of diseased or injured bone, the template providing mechanical support for surrounding bone while also providing a guide for ingrowth of bone tissue into the template.
  • Biodegradable and bioresorbable materials have been examined for use as implantable prostheses, and the like, and also as templates around which the body can regenerate various types of soft tissue. During or after soft tissue regeneration is complete, the biodegradable template is naturally eliminated from the body. It would be highly desirable to develop a biodegradable material having sufficient load bearing properties to permit its use as a bone substitute as well as a bone template so that natural bone tissue regenerates in the prosthetic template while the template degrades and is gradually eliminated from the body to be replaced by natural bone tissue.
  • biodegradable materials can be fabricated into three dimensional anatomical shapes having load bearing properties similar to or exceeding that of natural bone.
  • An implant fabricated of the biodegradable material has the capability of being rendered porous and can serve as a prosthetic template implant fostering ingrowth of new bone tissue.
  • the template can be implanted without first being rendered to its porous state. Porosity can be achieved after implantation by a faster rate of biodegradation of a pore forming component of the implant relative to a slower rate of degradation of a continuous or matrix component of the implant.
  • the implant may be rendered partially or wholly porous prior to implantation by partially or wholly removing the pore- forming component from the matrix component of the implant.
  • the implant has sufficient compressive strength and modulus to serve as a bone replacement prosthesis during that period wherein the body regenerates new natural bone within and to the shape of the implant.
  • the implant is replaced by natural bone as the implant biodegrades and by such process is displaced or eliminated from the body by natural processes.
  • the biodegradable porous implant serves as a supportive prosthesis, replacing damaged bone area and providing mechanical support.
  • the implant also provides a template for ingrowth of natural bone and regeneration of bone, particularly into the porous areas of the prosthetic template.
  • the implant is seeded with osteoblasts prior to implantation to provide regeneration sites for bone tissue. Bone cell growth, formation of bone nodules, and secretion of bone matrix by the seeded bone cells adds to the strength of the implant and to the rapid replacement with natural bone.
  • the rate at which the biodegradable and bioresorbable prosthetic template degrades or absorbs can be matched to the rate at which the natural bone regenerates within and into the prosthetic template. Upon elimination of the template from the body, it will then have been replaced by new bone.
  • the prosthetic templates of the present invention are biodegradable to products which either enter metabolic pathways and are thereby eliminated from the body (bioresorbed) or are eliminated from the body by other natural processes (e.g. in the urine) .
  • the templates preferably have a three-dimensional, anatomical shape conforming to the desired bone to be replaced.
  • the biodegradable templates are fabricated of polymers and by methods which result in implants which are capable of being rendered porous for tissue ingrowth while retaining sufficient mechanical strength to be suitable for replacement of load bearing bones.
  • the templates of the present invention possess a compressive strength of approximately 5MPa to 50MPa and a compressive modulus of approximately 50MPa to 500MPa as tested by an Instron Materials Testing Machine according to American Society for Testing and Materials (ASTM) Standard F451-86.
  • the values of 5MPa compressive strength and 50MPa compressive modulus correspond to the mid-range values for human trabecular bone.
  • the desired strength of the template will vary with the bone to be treated, e.g. , load-bearing or not.
  • the templates of the present invention have a high ultimate porosity capacity, resulting in a highly porous matrix containing a uniformly distributed and interconnected pore structure. Pore volume of the templates is approximately 20% to 50%, and the average pore diameter is approximately 50 to 250 ⁇ m. The pore volume and diameter also directly relate to the rate of tissue ingrowth and template degradation.
  • the porous template of the present invention accommodates large number of cells adhering to the template, permits cells to be easily distributed throughout the template, and allows an organized network of tissue constituents to be formed.
  • the template preferably promotes cell adhesion and permits the attached cells to retain differentiated cell function.
  • the prosthetic template comprises at least two components, a continuous matrix component and an included pore-forming component.
  • the matrix component comprises a biodegradable material having a rate of degradation which at least matches the rate at which the body regenerates natural bone tissue.
  • the pore-forming component is a material which differs from the matrix material such that it may be differentiated from the matrix component and ultimately be removed therefrom by differential dissolution or biodegradation to provide porosity to the prosthetic template either prior to or after implantation.
  • the biodegradable, bioresorbable prosthetic templates of the present invention preferably are formed of polymeric materials, the matrix polymer having a rate of degradation which is matched to the rate of tissue in-growth.
  • the matrix polymeric substance preferably ranges in weight average molecular weight from approximately 50,000 to 200,000. Crystallinity of the matrix polymer of implant is approximately 0 to 25%.
  • the molecular weight and molecular weight distribution of the matrix polymer of the template is related to the rate at which the template biodegrades.
  • a template having a matrix polymer of broad molecular weight distribution e.g., having a polydispersity index (Mw/Mn) greater than 2 fractions of the material exist in short to long polymeric chains.
  • the polydispersity index of the matrix polymer is preferably in the range of 3-6.
  • the molecular weight, molecular weight distribution and degree of crystallinity of the pore-forming polymer is also of significant concern.
  • the pore-forming polymer should biodegrade and/or bioresorb at a rate which is at least four times greater than that of the matrix polymer.
  • the pore-forming polymer should have a polydispersity index of at least 3 to provide for a controlled degradation over a period of time that avoids intolerable localized pH concentrations due to its degradation by-products.
  • the template may optionally contain additional ingredients such as therapeutic agents incorporated into the matrix or the pore-forming polymer for time release as that polymer degrades.
  • the template is seeded with osteoblasts prior to implantation to provide sites for promoted regeneration of bone tissue.
  • BIODEGRADABLE POLYMERS Biodegradable polymers are known, commercially available, or can be synthesized using known and published methods.
  • Examples of polymers useful in the present invention include poly(L-lactic acid) , poly(D L-lactic acid) , poly(D L-lactic-co-glycolic acid) , poly(glycolic acid), poly(epsilon-caprolactone) , polyorthoesters, and polyanhydrides. These polymers may be obtained in or prepared to the molecular weights and molecular weight distribution needed for service as either the matrix polymer or the pore-forming polymer by processes known in the art.
  • Preferred polymers are poly(alpha-hydroxy esters) . Suitable solvent systems are published in standard textbooks and publications.
  • THREE-DIMENSIONAL SHAPING Shape is integral to the function of bone prosthesis, therefore, the prosthetic templates of the present invention are preferably fabricated of materials and by methods which permit three-dimensional anatomical shaping.
  • Three-dimensional shaping may be achieved by forming the template in an anatomically-shaped mold, by machining a block matrix into the desired shape, or by laminating polymeric membranes together to form the desired anatomical shape. Necessary crevices, curves, and the like may be added to the prosthetic templates by machining, or by cutting using known methods such as scissors, scalpel, laser beams, and the like.
  • the prosthetic templates of the present invention contain a high ultimate porosity capacity. That is, the templates are fabricated in a manner which results in an implant capable of being rendered highly porous prior to implantation.
  • the matrix may be formed around included particles or fibers which particles or fibers are subsequently removed from the matrix by solvent dissolution or other methods of degradation, leaving a highly porous matrix template structure.
  • the particles or fibers embedded within the formed matrix may be retained in the template for dissolution or degradation in situ after implantation.
  • portions of the pore-creating material may be removed prior to implantation of the template providing a range of actual to ultimate porosities of the i plantable templates.
  • the ultimate porosity capacity may be defined as the percent porosity of the matrix after at least 90% of the pore forming material has been removed from the template, either in vitro or in vivo. In the present invention, it is preferred that the ultimate porosity capacity of the biodegradable/bioresorbable templates be in the range of 20% to 50% volume of the template.
  • a prosthetic template of the present invention is seeded with osteoblasts prior to implantation.
  • Donor osteoblast cells preferably autologous, are harvested and cultured as described in Puleo et al., J. Biomed. Mater. Res.. 25:711-723, 1991, which is hereby incorporated by reference.
  • the template may be prewetted, for example, ethanol and then medium.
  • a suspension of osteoblasts in growth medium is seeded in the template, for example by placing drops of the cell suspension onto or into the prosthetic template and allowing the suspension to wick into the polymeric foam.
  • the template may be implanted directly into a recipient or, preferably, the template may be placed in tissue culture for attachment.
  • the cells and template are incubated in culture medium in a tissue incubator at approximately 37°C and 5% C0 2 .
  • the amount of time required for cell attachment and growth will vary with the template, its size, porosity, and with the desired percentage of replacement bone in the template prior to implantation.
  • the incubation period will range from about 30 minutes to 24 hours for cell attachment, followed by approximately six hours to four weeks for cell growth and bone deposition in vitro. The longer the culture period, the greater the replacement of template material with natural bone tissue.
  • the transplanted cell population grows and the cells function normally, they will begin to secrete their own extra-cellular matrix for structural support. Concurrently, the continuously degrading polymer will be eliminated as the need for an artificial support diminishes. For example, after 21-30 days of culture, bone nodules form in the osteoblast-seeded implant. Calcium phosphate salts, collagen, and alkaline phosphatase may be analyzed as markers of bone matrix formation.
  • the biodegradable prosthetic templates of the present invention which have the features described above, including high mechanical strength necessary for replacement of load bearing bones, high ultimate porosity capacity to permit ingrowth of new bone tissue, and a rate of degradation approximately matching the rate of new tissue growth may, for example, be formed by the methods described below.
  • the templates of the present invention are formed by distributing within a polymeric matrix a pore creating substance. Regardless of the specific methods used to form the template, the product will include a three-dimensional, anatomically shaped prosthetic template having a high ultimate porosity capacity due to the presence of a pore creating substance dispersed within the matrix.
  • the pore creating substance may be formed for example of salts, polysaccharides, protein, polymers other than the matrix polymers, or other non-toxic materials such as gelatin which are, for example, soluble in a solvent which does not dissolve the matrix polymer; made fluid at a higher glass transition temperature (Tg) or melting temperature (Tm) than the matrix polymer; or otherwise differentiated from the matrix polymer so as to retain an independent structure from the polymeric matrix.
  • Tg glass transition temperature
  • Tm melting temperature
  • the temperature required to fluidize polymers is that which permits non-hindered flow of polymer chains.
  • this "flow temperature” is the glass transition temperature (Tg) .
  • this "flow temperature” is the melting temperature (Tm) .
  • flow temperature is meant to be that temperature which permits non-hindered flow of polymer chains and includes, as appropriate, Tg for amorphous polymers and Tm for at least semi-crystalline polymers.
  • the pore creating substance may be in the form of particles such as salt, which after forming a matrix in which the particles have been included, the particles are leached out or otherwise removed from the matrix leaving a polymeric matrix with high porosity.
  • the pore creating substance may be in the form of fibers such as polymeric fibers or webs dispersed within a formed polymeric matrix.
  • the dispersed fibers and the surrounding matrix possess differential rates of degradation, with the fibers being degraded at a faster rate than the matrix, thereby being removed from the template and creating a highly porous polymeric template.
  • Biocompatible prosthetic templates may be prepared, for example, by pouring a polymer solution into an anatomically-shaped mold.
  • the mold may contain a pore-creating substance.
  • the polymer solution being poured into the mold may include a dispersed pore-creating substance.
  • the polymeric solution containing dispersed pore-creating substance is cured into a polymeric foam by methods known in the art, including evaporation of solvent, heat curing, or irradiation.
  • the template may be formed by dispersing the pore-creating substance in a body of powdered polymer.
  • the pore-creating substance is a first polymer in fiber or web form dispersed in a body of powdered second polymer.
  • the second polymer has a lower flow temperature (Tf) such that when the dispersion is heated above the flow temperature of the powder, the powder is fluid, but the dispersed fibers are not.
  • Tf flow temperature
  • the fluid polymer is next solidified, e.g., by permitting the dispersion to return to ambient temperature, resulting in a polymeric matrix having entrapped therein the pore-forming substance.
  • the pore-creating substance may be removed from the matrix template.
  • fibers or particles may be dissolved out of the matrix by immersing the template in water or an appropriate solvent.
  • enzymes or chemical agents may be used to remove the pore-creating substance.
  • a first polymer is used to form the template matrix and a second polymer is used to form the pore-creating substance dispersed within the first polymer. Both first and second polymers are biodegradable but the second degrades at a faster rate than the first polymer, e.g., approximately two to eight times faster, and preferably about four times faster creating the desired porous template matrix for ingrowth and proliferation of cells.
  • poly(glycolic acid) (PGA) fiber meshes may be dispersed within poly(L-lactic acid) (PLLA) .
  • PLLA poly(L-lactic acid)
  • the PGA fiber mesh Upon curing of the PLLA matrix, the PGA fiber mesh is embedded within the PLLA matrix.
  • the PGA fibers biodegrade at a more rapid rate than PLLA, thus creating a template having a high ultimate porosity capacity.
  • the pore creating substance may be formed of a low molecular weight polymer while the matrix is formed of a high molecular weight polymer. Because the low molecular weight polymers degrade at a faster rate than the high molecular weight polymers an implant having a desired rate of degradation of each of the pore creating substance and the matrix can be formed.
  • biodegradable prosthetic templates formed as described above may be prepared in molds having the desired three-dimensional shape.
  • the formed polymeric matrix may then be machined and/or modified by methods known in the art to form the precise contours and shapings required.
  • a block matrix polymer may be formed as described above and then machined and/or otherwise cut to the desired shape by known methods. Crevices, smoothing, and other adjustments to the shaped anatomic prosthesis may be performed, for example by machining tools, knives, scissors, laser beams and the like.
  • the template may be directly implanted or may be further treated to induce porosity and to add additional beneficial agents.
  • the template is treated to induce porosity by dissolving the pore- forming material in a solvent which does not dissolve the matrix polymer.
  • a faster rate than the template matrix such as PGA fibers which degrade within months of implantation in a PLLA matrix which may take more than one year to degrade, permits gradual replacement of the pore- creating substance with growing bone cells.
  • the resorbing pore-creating substance is gradually replaced with newly formed bone tissue, maintaining a mechanically strong bone prosthesis.
  • the more slowly degrading polymeric matrix is then resorbed and replaced with bone tissue proliferating from the network of growing tissue already present throughout the prosthetic template.
  • therapeutic agents may be incorporated into the polymeric matrix or into the pore- creating substance for timed release of these agents in situ.
  • Agents such as growth factors, antibiotics, immune stimulators, immune suppressants, and the like may be incorporated into the polymeric matrix or the pore-creating substance, and are slowly released as the matrix is degraded.
  • the biodegradable, bioresorbable prosthetic templates of the present invention are implanted in desired sites in bone.
  • the templates may be implanted as a shaped polymeric prosthesis containing a pore-creating substance having an ultimate ' porosity capability for ingrowth of new bone tissue.
  • the pore-creating substance may be removed in vivo, or alternatively, the template may be pretreated prior to implantation to partially or totally remove the pore-creating substance.
  • the template is implanted for in situ ingrowth of bone tissue at the site of implantation.
  • the template is seeded with osteoblast cells prior to implantation, and may be cultured to permit initial growth and deposition of bone matrix in vitro, providing for implantation a template containing growing viable sites of bone tissue as described above.
  • Porcine skin gelatin (20g) (Sigma Chemical Company, St. Louis MO) was dissolved in 100ml of distilled, deionized water maintained at 50°C in a water bath. The solution was stirred continuously, using a magnetic stirrer, for approximately 30 minutes until all the gelatin had dissolved. Toluene (730ml) and chloroform (230ml) were added to a four liter baffled beaker to which 20ml of a surfactant Arlacel 83 (Sigma) was added. The solution was mixed continuously using a propeller stirrer as the 100ml of gelatin solution was slowly added using a 10ml pipette.
  • the stirrer and baffles were removed and the gelatin microspheres produced were separated from the solution using a fine mesh sieve (53 ⁇ m) .
  • the gelatin microspheres were then washed in 100ml of chloroform and allowed to dry in a fume hood for 24 hours and then in a lyophilizer for 24 hours.
  • the dried microspheres were ground gently using a mortar and pestle in order to break up any aggregates and then sieved into the following size ranges: 53-250 ⁇ m; 250-500 ⁇ m; 500-1000 ⁇ m; greater than lOOO ⁇ m.
  • the separated microspheres were then stored in a vacuum desiccator until needed.
  • a composite material consisting of gelatin microspheres embedded in a poly(DL-lactic-co-glycolic acid) (PLGA) matrix was formed by the following procedure. Several grams of PLGA 50:50 (Medisorb, Cincinnati, OH) were ground into a fine powder using a micro-mill for approximately 20 minutes. (The ratio 50:50 stands for the copolymer ratio of lactic acid to glycolic acid.) The ground PLGA (0.04g) was mixed with 0.04g of gelatin microspheres in the size range of 250-500 ⁇ m. This combination is calculated to yield a final foam having approximately 50% porosity once the gelatin is removed. This mixture was then poured into a cylindrical Teflon mold, 6mm in diameter.
  • the mold was then closed and moderate pressure, e.g., between finger and thumb, was applied to compress the PLGA/gelatin mixture. The approximate height of the cylindrical mold was 4-5mm.
  • the mold was then cooled at 25°C, and its contents removed for microscopic examination. Inspection by light microscopy and by scanning electron microscopy indicated the PLGA had molded about the gelatin microspheres and had formed a structurally intact composite.
  • the gelatin microspheres were removed from the matrix by the following leaching method: the PLGA/gelatin composite was placed in 15ml of distilled, deionized water at 37°C under agitation for 20 hours. The water was then removed and replaced with fresh distilled deionized water. After further agitation for four hours, the PLGA foam was removed and dried in a lyophilizer for 24 hours. Analysis by light microscopy and scanning electron microscopy indicated the gelatin beads had been leached out leaving an intact, highly porous, PLGA foam. EXAMPLE 2 PREPARATION OF ADDITIONAL PLGA/GELATIN COMPOSITES
  • Example 1 The procedure described for Example 1 was repeated, except that gelatin microspheres in a size range of 53- 250 ⁇ m were utilized to form an intact, highly porous, PLGA foam having a smaller pore size than described for Example 1. In a similar fashion, the procedure of Example 1 was followed except that gelatin microspheres in the size range of 500-1000 ⁇ m were used to generate and intact, highly porous foam having a larger pore size than the foam described for Example 1.
  • Example 1 The procedure described in Example 1 was repeated except that PLGA 85:15 (Medisorb) was utilized to form an intact, high porous PLGA foam which degrades more slowly than that described for Example 1.
  • PLGA 85:15 Medisorb
  • Example 1 The procedure described for Example 1 was followed except that PLGA 70:30 (Polysciences, Warrington, PA) was used, resulting in a polymer foam which degrades more slowly than that described for Example 1.
  • PLGA 70:30 Polysciences, Warrington, PA
  • Example 1 The procedure described for Example 1 was followed except that the polymer utilized was poly(L-lactic acid) (PLLA) of approximately 2,000 molecular weight (Polysciences) , resulting in an intact, highly porous foam which degrades very fast as compared with the polymer of Example 1 due to the low molecular weight of the polymer used.
  • PLLA poly(L-lactic acid)
  • Example 2 The procedure as described for Example 1 was followed except that 0.06 grams of the ground PLGA was mixed with 0.02 grams of the gelatin microspheres, resulting in a less porous but stronger polymeric foam, e.g., of approximately
  • Example 16 PREPARATION OF PLGA/NACL COMPOSITE AND PLGA FOAM The procedure of Example 1 was followed except that sodium chloride particles in the size range of 250-500 ⁇ m were utilized, resulting in an intact, highly porous PLGA foam as was prepared in Example 1.
  • EXAMPLE 4 PREPARATION OF PLLA/NACL COMPOSITE AND PLLA FOAM
  • PLLA approximately 100,000 molecular weight (Medisorb) was used and the mold was placed in a convection oven at 195°C for 90 minutes.
  • the higher temperature was required, for example, because homopolymer ⁇ of high molecular weight such as PLLA form crystallites.
  • T m melting temperature
  • the melting temperature of PLLA is approximately 180°C.
  • the resultant PLLA foam was similar to that prepared as described in Example 1.
  • Example 4 The procedure as described for Example 4 was followed except that 0.1 gram of ground PLLA and 0.1 gram of PGA fibers of approximately lOO ⁇ m diameter and approximately lmm length (Ethicon, Summerville, NJ) were combined. The PGA fibers thus substituted for the NAC1 particles. PGA fibers have a melting temperature of 230°C. The resulting PLLA/PGA composite had an ultimate porosity capacity of approximately 50%.
  • the compressive strength and modulus of excised implants is measured, for example according to American Society for Testing and Materials (ASTM) Standard 451-86 for bone cements. This consists of compressing the speciment to failure in an Instron 8501 materials testing machine. For example, the compression speed is 1 mm per minute, and the failure load is the load at 2% offset, fracture, or upper yield point, whichever occurs first.
  • the compressive modulus is calculated from the initial linear portion of the load deformation curve.
  • Biodegradation is analyzed by gel permeation chromatography.
  • the number and weight average of the polymer is measured directly from samples solubilized in chloroform, using a refractive index detector.
  • Bone ingrowth into the implant is quantitated from histological sections by measuring area fraction of bone with a computerized image analysis system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un gabarit biodégradable, biorésorbable et tridimensionnel servant à réparer ou à remplacer un os souffrant de dégénérescence ou ayant subi une lésion, et conférant une résistance mécanique audit tout en constituant un guide pour la croissance du tissu osseux. La matrice biodégradable peut comporter des pores répartis dans son volume ou une substance créant des pores peut être dispersée à l'intérieur de ladite matrice. La substance de création de pores peut être un sel, de la gélatine, un polysaccharide, une protéine ou des polymères synthétiques ou naturels. La matrice biodégradable peut être constituée à partir de matériaux, tels que l'acide poly(L-lactique) ou l'acide poly(DL-lactique-co-glycolique).
PCT/US1994/008265 1993-07-23 1994-07-22 Gabarits de regeneration osseuse WO1995003011A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74028/94A AU7402894A (en) 1993-07-23 1994-07-22 Bone regeneration templates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/096,780 1993-07-23
US08/096,780 US5522895A (en) 1993-07-23 1993-07-23 Biodegradable bone templates

Publications (2)

Publication Number Publication Date
WO1995003011A1 true WO1995003011A1 (fr) 1995-02-02
WO1995003011A9 WO1995003011A9 (fr) 1995-03-02

Family

ID=22259039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008265 WO1995003011A1 (fr) 1993-07-23 1994-07-22 Gabarits de regeneration osseuse

Country Status (3)

Country Link
US (1) US5522895A (fr)
AU (1) AU7402894A (fr)
WO (1) WO1995003011A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010428A1 (fr) * 1994-10-03 1996-04-11 Otogen Corporation Implants biomedicaux presentant des caracteristiques differentes de biodegradabilite
WO1997013533A1 (fr) * 1995-10-11 1997-04-17 Osteobiologics, Inc. Materiau pour implants biodegradable, moulable façonnable a la main
EP0891783A1 (fr) * 1997-07-16 1999-01-20 Isotis B.V. Dispositif pour la régénération osseuse consistant d'un copolyester thermoplastique biodégradable et de cellules cultivées
WO1999033447A3 (fr) * 1997-12-30 1999-08-19 Massachusetts Inst Technology Regeneration de tissus dans des sites de lesions internes
US6110484A (en) * 1998-11-24 2000-08-29 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
US6228117B1 (en) 1997-07-16 2001-05-08 Isotis B.V. Device for tissue engineering bone
US6299650B1 (en) 1996-03-01 2001-10-09 Isotis N.V. Method for in vitro production of bone
RU2533457C1 (ru) * 2013-04-19 2014-11-20 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантации и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Биоактивный резорбируемый пористых 3d-матрикс для регенеративной медицины и способ его получения
WO2015172212A1 (fr) * 2014-05-15 2015-11-19 Aguedo Aragones Dispositif hybride réabsorbable pour la régénération tissulaire guidée

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5702446A (en) * 1992-11-09 1997-12-30 Board Of Regents, The University Of Texas System Bone prosthesis
US5947893A (en) * 1994-04-27 1999-09-07 Board Of Regents, The University Of Texas System Method of making a porous prothesis with biodegradable coatings
JP2987064B2 (ja) * 1994-09-12 1999-12-06 グンゼ株式会社 人工硬膜
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
CN1136922C (zh) * 1995-05-01 2004-02-04 株式会社三养社 可植入的可生物再吸收的膜及其制备方法
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US5674292A (en) 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
AU6493598A (en) * 1997-04-16 1998-11-11 White Spot Ag Biodegradable osteosynthesis implant
US6017366A (en) * 1997-04-18 2000-01-25 W. L. Gore & Associates, Inc. Resorbable interposition arthroplasty implant
US5980564A (en) * 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
WO1999009149A1 (fr) * 1997-08-01 1999-02-25 Massachusetts Institute Of Technology Matrices de polymeres tridimensionnelles
US6241771B1 (en) * 1997-08-13 2001-06-05 Cambridge Scientific, Inc. Resorbable interbody spinal fusion devices
US7147666B1 (en) * 1997-11-26 2006-12-12 Bernard Francis Grisoni Monolithic implants with openings
US6187329B1 (en) * 1997-12-23 2001-02-13 Board Of Regents Of The University Of Texas System Variable permeability bone implants, methods for their preparation and use
US5899939A (en) * 1998-01-21 1999-05-04 Osteotech, Inc. Bone-derived implant for load-supporting applications
US6123731A (en) 1998-02-06 2000-09-26 Osteotech, Inc. Osteoimplant and method for its manufacture
US6083264A (en) * 1998-06-30 2000-07-04 Mcdonnell Douglas Corporation Implant material for replacing or augmenting living bone tissue involving thermoplastic syntactic foam
US7022522B2 (en) 1998-11-13 2006-04-04 Limin Guan Macroporous polymer scaffold containing calcium phosphate particles
US6165486A (en) * 1998-11-19 2000-12-26 Carnegie Mellon University Biocompatible compositions and methods of using same
US6302916B1 (en) * 1998-12-24 2001-10-16 Biopro, Inc. Polyurethane and so forth containing joints
AU770579B2 (en) 1999-04-16 2004-02-26 Wm. Marsh Rice University Poly(propylene fumarate) cross linked with poly(ethylene glycol)
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
US6355699B1 (en) * 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
ITVI20000025U1 (it) * 2000-04-07 2001-10-07 Tecres Spa Dispositivo distanziatore temporaneo per il trattamento chirurgico del ginocchio
US6395033B1 (en) * 2000-04-10 2002-05-28 Tyco Healthcare Group Lp Dynamic fusion mechanostat devices
US6423252B1 (en) * 2000-06-23 2002-07-23 Ethicon, Inc. Methods of making micropatterned foams
FI20001696L (fi) * 2000-07-21 2002-01-22 Jvs Polymers Oy Biologisesti aktiivinen materiaali
US6599516B1 (en) * 2000-09-14 2003-07-29 Etex Corporation Malleable implant containing solid element that resorbs or fractures to provide access channels
US6695845B2 (en) 2000-10-16 2004-02-24 Robert A Dixon Method and apparatus utilizing interference fit screw shanks for nonmetallic spinal stabilization
US6605090B1 (en) 2000-10-25 2003-08-12 Sdgi Holdings, Inc. Non-metallic implant devices and intra-operative methods for assembly and fixation
US6656181B2 (en) 2000-11-22 2003-12-02 Robert A Dixon Method and device utilizing tapered screw shanks for spinal stabilization
US7192604B2 (en) * 2000-12-22 2007-03-20 Ethicon, Inc. Implantable biodegradable devices for musculoskeletal repair or regeneration
US6575986B2 (en) 2001-02-26 2003-06-10 Ethicon, Inc. Scaffold fixation device for use in articular cartilage repair
US6743232B2 (en) 2001-02-26 2004-06-01 David W. Overaker Tissue scaffold anchor for cartilage repair
US6913765B2 (en) * 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
US20030171546A1 (en) * 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030003127A1 (en) * 2001-06-27 2003-01-02 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
ATE393183T1 (de) * 2001-06-28 2008-05-15 Univ Wm Marsh Rice Photoquervernetzung von biologischen materialien aus fumarsäurediethylester/poly(propylenfumarat)
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
US20060142765A9 (en) * 2001-10-15 2006-06-29 Dixon Robert A Vertebral implant for bone fixation or interbody use
WO2003041568A2 (fr) * 2001-11-15 2003-05-22 University Of Medicine & Dentistry Of New Jersey Matrice tridimensionnelle pour produire des equivalents de tissu vivant
US7629388B2 (en) * 2001-11-20 2009-12-08 William Marsh Rice University Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion
US6712850B2 (en) * 2001-11-30 2004-03-30 Ethicon, Inc. Porous tissue scaffolds for the repair and regeneration of dermal tissue
CA2475110C (fr) * 2002-02-05 2010-03-23 Cambridge Scientific, Inc. Compositions osteoconductrices bioresorbables destinees a la regeneration osseuse
US7879107B2 (en) * 2002-02-20 2011-02-01 The Cleveland Clinic Foundation Composition and method for inducing bone growth and healing
US6923833B2 (en) * 2002-04-09 2005-08-02 Ray C. Wasielewski Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
US8187326B2 (en) 2002-05-22 2012-05-29 Advanced Technologies And Regenerative Medicine, Llc. Attachment of absorbable tissue scaffolds to fixation devices
US6989034B2 (en) 2002-05-31 2006-01-24 Ethicon, Inc. Attachment of absorbable tissue scaffolds to fixation devices
US6793678B2 (en) 2002-06-27 2004-09-21 Depuy Acromed, Inc. Prosthetic intervertebral motion disc having dampening
EP2324867B1 (fr) 2002-07-12 2014-06-18 Cook Medical Technologies LLC Ballons d'angioplastie revêtis d'agents pharmaceutiques en forme expansée
US7309361B2 (en) * 2002-10-23 2007-12-18 Wasielewski Ray C Biologic modular tibial and femoral component augments for use with total knee arthroplasty
US20050251267A1 (en) * 2004-05-04 2005-11-10 John Winterbottom Cell permeable structural implant
BRPI0407142A (pt) 2003-02-14 2006-01-10 Depuy Spine Inc Dispositivo de fusão intervertebral formado in situ
EP1608292A4 (fr) * 2003-03-13 2007-10-31 Univ Rice William M Composite injectable et materiau de remplacement d'os prefabrique et procede de production de ce materiau de remplacement d'os
US8007823B2 (en) * 2003-04-03 2011-08-30 Corporation De L'ecole Polytechnique De Montreal Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof
JP2007521843A (ja) 2003-05-15 2007-08-09 バイオメリクス コーポレーション 網状化エラストマー系マトリックス、その製造、及び移植可能な装置における使用
US20040267367A1 (en) 2003-06-30 2004-12-30 Depuy Acromed, Inc Intervertebral implant with conformable endplate
US7699879B2 (en) * 2003-10-21 2010-04-20 Warsaw Orthopedic, Inc. Apparatus and method for providing dynamizable translations to orthopedic implants
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
US7815826B2 (en) * 2004-05-12 2010-10-19 Massachusetts Institute Of Technology Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like
US20060029633A1 (en) * 2004-08-03 2006-02-09 Arthrotek, Inc Biological patch for use in medical procedures
US8980300B2 (en) 2004-08-05 2015-03-17 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
EP1816987A4 (fr) 2004-11-09 2011-03-09 Proxy Biomedical Ltd Empilement de tissus
US8771294B2 (en) 2004-11-26 2014-07-08 Biomerix Corporation Aneurysm treatment devices and methods
WO2006108065A2 (fr) * 2005-04-05 2006-10-12 Elixir Medical Corporation Dispositifs medicaux implantables degradables
US8128696B2 (en) 2005-05-11 2012-03-06 Hermann Mayr System and implant for ligament reconstruction or bone reconstruction
US20070038299A1 (en) * 2005-08-12 2007-02-15 Arthrotek, Inc Multilayer microperforated implant
US8034110B2 (en) 2006-07-31 2011-10-11 Depuy Spine, Inc. Spinal fusion implant
US8637064B2 (en) * 2006-09-20 2014-01-28 Warsaw Orthopedic, Inc. Compression molding method for making biomaterial composites
WO2008070863A2 (fr) 2006-12-07 2008-06-12 Interventional Spine, Inc. Implant intervertébral
CN101245313A (zh) * 2007-02-13 2008-08-20 刘青 三维细胞培养插入件、其制造方法、成套用具及用途
US20080206297A1 (en) * 2007-02-28 2008-08-28 Roeder Ryan K Porous composite biomaterials and related methods
US8900307B2 (en) 2007-06-26 2014-12-02 DePuy Synthes Products, LLC Highly lordosed fusion cage
US8551173B2 (en) 2008-01-17 2013-10-08 DePuy Synthes Products, LLC Expandable intervertebral implant and associated method of manufacturing the same
US8685432B2 (en) * 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
BRPI0910325A8 (pt) 2008-04-05 2019-01-29 Synthes Gmbh implante intervertebral expansível
DK2274023T3 (da) 2008-04-10 2020-03-16 Bonus Therapeutics Ltd Knoglelignende proteseimplantater
WO2010066203A1 (fr) * 2008-12-10 2010-06-17 Anhui Zhongren Technology Co., Ltd. Composition à libération contrôlée
WO2010096254A1 (fr) * 2009-02-21 2010-08-26 The Trustees Of The University Of Pennsylvania Composites microsphères/nanofibres pour administration de médicaments, facteurs de croissance et autres agents
US9526620B2 (en) 2009-03-30 2016-12-27 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US8801801B2 (en) * 2009-04-03 2014-08-12 Biomerix Corporation At least partially resorbable reticulated elastomeric matrix elements and methods of making same
US9050176B2 (en) 2009-04-03 2015-06-09 Biomerix Corporation At least partially resorbable reticulated elastomeric matrix elements and methods of making same
WO2010128039A1 (fr) * 2009-05-07 2010-11-11 Dsm Ip Assets B.V. Composite biodégradable comprenant un polymère biodégradable et une fibre de verre
US9168138B2 (en) 2009-12-09 2015-10-27 DePuy Synthes Products, Inc. Aspirating implants and method of bony regeneration
US9393129B2 (en) 2009-12-10 2016-07-19 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US8979860B2 (en) 2010-06-24 2015-03-17 DePuy Synthes Products. LLC Enhanced cage insertion device
US9592063B2 (en) 2010-06-24 2017-03-14 DePuy Synthes Products, Inc. Universal trial for lateral cages
TW201215379A (en) 2010-06-29 2012-04-16 Synthes Gmbh Distractible intervertebral implant
US20130184835A1 (en) 2010-07-09 2013-07-18 Board Of Regents Of The Unversity Of Texas System Biodegradable scaffolds
US9402732B2 (en) 2010-10-11 2016-08-02 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
EP2623134A1 (fr) * 2012-02-01 2013-08-07 Phrontier S.A.R.L. Matrice d'implant à base d'un mélange polymère
ES2475166T3 (es) * 2012-02-01 2014-07-10 Bioenergy Capital Ag Matriz de implante de una mezcla de pol�meros
WO2014123978A2 (fr) 2013-02-05 2014-08-14 University Of Utah Research Foundation Dispositifs implantables pour défauts d'os ou d'articulation
US9717601B2 (en) 2013-02-28 2017-08-01 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
US9522070B2 (en) 2013-03-07 2016-12-20 Interventional Spine, Inc. Intervertebral implant
EP3129075B1 (fr) 2014-04-10 2024-09-18 Bonus Therapeutics Ltd. Compositions pour la réparation des os
WO2016071816A1 (fr) * 2014-11-06 2016-05-12 Tecres S.P.A. Dispositif d'écartement permettant l'absorption/l'élution
US11292909B2 (en) * 2014-12-19 2022-04-05 Earth Renewable Technologies Extrudable polymer composition and method of making molded articles utilizing the same
US11426290B2 (en) 2015-03-06 2022-08-30 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
AU2017286836B2 (en) 2016-06-28 2022-07-28 Eit Emerging Implant Technologies Gmbh Expandable and angularly adjustable intervertebral cages with articulating joint
JP6995789B2 (ja) 2016-06-28 2022-01-17 イーアイティー・エマージング・インプラント・テクノロジーズ・ゲーエムベーハー 拡張可能かつ角度調節可能な椎間ケージ
KR20190038833A (ko) 2016-07-11 2019-04-09 보누스 테라퓨틱스 리미티드 조직 재생용 세포 조성물
US10888433B2 (en) 2016-12-14 2021-01-12 DePuy Synthes Products, Inc. Intervertebral implant inserter and related methods
US10398563B2 (en) 2017-05-08 2019-09-03 Medos International Sarl Expandable cage
US11344424B2 (en) 2017-06-14 2022-05-31 Medos International Sarl Expandable intervertebral implant and related methods
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
US11446156B2 (en) 2018-10-25 2022-09-20 Medos International Sarl Expandable intervertebral implant, inserter instrument, and related methods
US11426286B2 (en) 2020-03-06 2022-08-30 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
CN111978588B (zh) * 2020-08-05 2022-05-03 广东省医疗器械研究所 一种大孔水凝胶及其制备方法和应用
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
US11752009B2 (en) 2021-04-06 2023-09-12 Medos International Sarl Expandable intervertebral fusion cage
WO2022260988A1 (fr) * 2021-06-09 2022-12-15 President And Fellows Of Harvard College Encre biologique imprimable et procédé d'impression d'un modèle tissulaire/organique ou d'une construction thérapeutique
US12090064B2 (en) 2022-03-01 2024-09-17 Medos International Sarl Stabilization members for expandable intervertebral implants, and related systems and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4553272A (en) * 1981-02-26 1985-11-19 University Of Pittsburgh Regeneration of living tissues by growth of isolated cells in porous implant and product thereof
US4661536A (en) * 1985-02-19 1987-04-28 The Dow Chemical Company Process for the preparation of hard tissue prosthetics
GB2215209A (en) * 1988-03-14 1989-09-20 Osmed Inc Biodegradable, osteogenic, bone graft substitute

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485097A (en) * 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4655777A (en) * 1983-12-19 1987-04-07 Southern Research Institute Method of producing biodegradable prosthesis and products therefrom
US5041138A (en) * 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
IT1215881B (it) * 1988-02-16 1990-02-22 Giancarlo Foresti Sussidio chirurgico ad azione osteotropa.
DE3825211A1 (de) * 1988-07-25 1990-02-01 Henkel Kgaa Verbesserte koerperresorbierbare knochenwachse (iii)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4553272A (en) * 1981-02-26 1985-11-19 University Of Pittsburgh Regeneration of living tissues by growth of isolated cells in porous implant and product thereof
US4661536A (en) * 1985-02-19 1987-04-28 The Dow Chemical Company Process for the preparation of hard tissue prosthetics
GB2215209A (en) * 1988-03-14 1989-09-20 Osmed Inc Biodegradable, osteogenic, bone graft substitute

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010428A1 (fr) * 1994-10-03 1996-04-11 Otogen Corporation Implants biomedicaux presentant des caracteristiques differentes de biodegradabilite
US6156068A (en) * 1995-10-11 2000-12-05 Osteobiologics, Inc. Method of resurfacing a femoral condyle
WO1997013533A1 (fr) * 1995-10-11 1997-04-17 Osteobiologics, Inc. Materiau pour implants biodegradable, moulable façonnable a la main
US5716413A (en) * 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
US5863297A (en) * 1995-10-11 1999-01-26 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
US6203573B1 (en) 1995-10-11 2001-03-20 Osteobiologics, Inc. Method of making biodegradable implant material and products made therefrom
US6299650B1 (en) 1996-03-01 2001-10-09 Isotis N.V. Method for in vitro production of bone
US6228117B1 (en) 1997-07-16 2001-05-08 Isotis B.V. Device for tissue engineering bone
EP0891783A1 (fr) * 1997-07-16 1999-01-20 Isotis B.V. Dispositif pour la régénération osseuse consistant d'un copolyester thermoplastique biodégradable et de cellules cultivées
WO1999033447A3 (fr) * 1997-12-30 1999-08-19 Massachusetts Inst Technology Regeneration de tissus dans des sites de lesions internes
US6110484A (en) * 1998-11-24 2000-08-29 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
US6277394B1 (en) 1998-11-24 2001-08-21 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
RU2533457C1 (ru) * 2013-04-19 2014-11-20 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантации и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Биоактивный резорбируемый пористых 3d-матрикс для регенеративной медицины и способ его получения
WO2015172212A1 (fr) * 2014-05-15 2015-11-19 Aguedo Aragones Dispositif hybride réabsorbable pour la régénération tissulaire guidée

Also Published As

Publication number Publication date
AU7402894A (en) 1995-02-20
US5522895A (en) 1996-06-04

Similar Documents

Publication Publication Date Title
US5522895A (en) Biodegradable bone templates
WO1995003011A9 (fr) Gabarits de regeneration osseuse
DE60019354T2 (de) Verfahren zur Knorpelgeweberegeneration
Chim et al. A comparative analysis of scaffold material modifications for load-bearing applications in bone tissue engineering
US7968026B1 (en) Three-dimensional bioresorbable scaffolds for tissue engineering applications
Thomson et al. Hydroxyapatite fiber reinforced poly (α-hydroxy ester) foams for bone regeneration
Thomson et al. Biodegradable polymer scaffolds to regenerate organs
DE69625828T2 (de) Giesfähiges, handverformbares, bioresorbierbares implantatmaterial
US6306169B1 (en) Tissue implant
US7524335B2 (en) Fiber-reinforced, porous, biodegradable implant device
US7022522B2 (en) Macroporous polymer scaffold containing calcium phosphate particles
EP1005379B1 (fr) Composites biodegradables
EP0707498B1 (fr) Prothese implantable, trousse et dispositif de fabrication
EP1027897B1 (fr) Systèmes de régénération du tissus de cartilage
US20020143403A1 (en) Compositions and methods for biomedical applications
EP3351273A1 (fr) Préparation de supports de tissus se régénérant
WO2008106625A2 (fr) Biomatériaux composites poreux et procédés associés
EP2249888B1 (fr) Composite d'implant osseux
US20170303980A1 (en) Natural Polymer-Based Porous Orthopedic Fixation Screw for Bone Repair and Regeneration
US8062655B2 (en) Composite scaffold structure
Thomas et al. Tissue Engineering Systems
US20250058023A1 (en) Shaped amalgamated cartilage grafts and methods for making and using same
Thomson et al. A Novel Biodegradable Poly (Lactic-co-Glycolic Acid) Foam for Bone Regeneration
Joshi Scaffolds for bone tissue engineering
Chen Design and fabrication of multifunctional polymer based nanocomposites for bone tissue engineering

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-19,DESCRIPTION,REPLACED BY NEW PAGES 1-18;PAGES 20-24,CLAIMS,REPLACED BY NEW PAGES 19-23;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA